دورية أكاديمية
أعرض في EDS

Impact of magnesium supplementation on clinical outcome and disease progression of patients with diabetic nephropathy: a prospective randomized trial.

التفاصيل البيبلوغرافية
العنوان: Impact of magnesium supplementation on clinical outcome and disease progression of patients with diabetic nephropathy: a prospective randomized trial.
المؤلفون: Halawa N; Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt., Elsaid TW; Nephrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., El Wakeel LM; Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt., Shawki MA; Clinical Pharmacy Department, Faculty of Pharmacy-Ain Shams University, African Union Organization, Cairo 11566, Egypt.
المصدر: Therapeutic advances in chronic disease [Ther Adv Chronic Dis] 2023 Dec 12; Vol. 14, pp. 20406223231214641. Date of Electronic Publication: 2023 Dec 12 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: SAGE Publications Country of Publication: United States NLM ID: 101532140 Publication Model: eCollection Cited Medium: Print ISSN: 2040-6223 (Print) Linking ISSN: 20406223 NLM ISO Abbreviation: Ther Adv Chronic Dis Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Los Angeles : SAGE Publications
مستخلص: Background: Magnesium (Mg) deficiency is closely linked with proteinuria.
Objectives: To assess the impact of oral Mg citrate supplementation on the clinical outcome of diabetic nephropathy (DN) patients.
Design: This was a prospective, randomized, controlled, open-label study.
Methods: Sixty DN patients were recruited from Nephrology and Endocrinology departments, Ain Shams University Hospitals, Cairo, Egypt. Patients were assigned by stratified randomization based on their Mg status, to either Mg citrate group, ( n  = 30), who received the standard regimen + oral Mg citrate 2.25 g/day or Control group, ( n  = 30), who received the standard regimen only. The primary endpoint was a change in urinary albumin to creatinine ratio (UACR) after 12 weeks. Secondary outcomes were insulin resistance, glycemic control, lipid profile, serum osteocalcin, quality of life (QoL) and Mg tolerability.
Results: Out of a total of 60 patients enrolled, only 54 patients (26 in Mg citrate group and 28 in the control group) completed the study. Groups were comparable at baseline. The UACR median percent reduction was significantly higher in the Mg citrate group (-6.87%) versus (-0.9%) in the Control group, p  = 0.001. After 12 weeks, the estimated glomerular filtration rate significantly improved in the Mg citrate group versus Control group ( p  = 0.001). Comparable change was observed in glycemic indices. Lipid profile significantly improved in the Mg citrate group versus Control group ( p  = 0.001). Serum osteocalcin levels significantly declined in the Mg citrate group ( p  = 0.001) versus control group. Regarding QoL, the total score and all domains significantly improved in the Mg citrate group compared to control. The Mg supplement was tolerable with only mild reported side effects that required no intervention.
Conclusion: Oral Mg citrate supplementation improved microalbuminuria in DN patients. It also had favorable effects on serum osteocalcin, lipid profile and QoL with no reported major side effects.
Trial Registration: ClinicalTrials.gov identifier: NCT03824379.
Competing Interests: The authors declare that there is no conflict of interest.
(© The Author(s), 2023.)
References: J Ren Nutr. 2022 Jan;32(1):102-111. (PMID: 34531112)
Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):43-54. (PMID: 33213186)
Clin Nutr. 2014 Oct;33(5):879-88. (PMID: 24182515)
Nutrients. 2021 Mar 30;13(4):. (PMID: 33808247)
Stress Health. 2021 Dec;37(5):1000-1009. (PMID: 33864354)
World J Diabetes. 2015 Aug 25;6(10):1152-7. (PMID: 26322160)
Diabetologia. 2009 Feb;52(2):208-12. (PMID: 19057893)
Technol Health Care. 2018;26(S1):379-387. (PMID: 29758962)
J Hum Nutr Diet. 2017 Oct;30(5):621-633. (PMID: 28150351)
Am J Ther. 2001 Sep-Oct;8(5):345-57. (PMID: 11550076)
Arch Med Sci. 2012 May 9;8(2):270-6. (PMID: 22662000)
Rev Diabet Stud. 2013 Summer-Fall;10(2-3):88-100. (PMID: 24380085)
Magnes Res. 2003 Sep;16(3):183-91. (PMID: 14596323)
Kidney Int. 1985 Nov;28(5):783-90. (PMID: 3878905)
J Am Coll Nutr. 1986;5(6):507-19. (PMID: 3537077)
Biol Trace Elem Res. 2020 Jan;193(1):23-35. (PMID: 30835085)
Diabetes Care. 2012 Jul;35(7):1591-7. (PMID: 22498805)
Clin Nutr. 2011 Jun;30(3):359-64. (PMID: 21288611)
Curr Osteoporos Rep. 2017 Jun;15(3):178-186. (PMID: 28429254)
Biometals. 2021 Aug;34(4):715-736. (PMID: 33959846)
Am J Nephrol. 2000 May-Jun;20(3):187-92. (PMID: 10878399)
Eur J Clin Nutr. 1999 Apr;53(4):255-61. (PMID: 10334649)
Cochrane Database Syst Rev. 2020 Sep 21;9:CD009402. (PMID: 32956536)
Med Sci Monit. 2010 Jun;16(6):CR307-312. (PMID: 20531272)
Am J Kidney Dis. 2003 May;41(5):997-1007. (PMID: 12722034)
Chronic Illn. 2008 Dec;4(4):257-63. (PMID: 19091934)
Mater Sci Eng C Mater Biol Appl. 2013 Jul 1;33(5):2757-65. (PMID: 23623093)
Ann Intern Med. 2021 Mar;174(3):385-394. (PMID: 33166222)
Adv Nutr. 2013 May 01;4(3):378S-83S. (PMID: 23674807)
Am Fam Physician. 2009 Jul 15;80(2):157-62. (PMID: 19621856)
J Clin Endocrinol Metab. 1998 Aug;83(8):2742-8. (PMID: 9709941)
Ann Intern Med. 1999 Mar 16;130(6):461-70. (PMID: 10075613)
Diabetes Obes Metab. 2011 Mar;13(3):281-4. (PMID: 21205110)
Rev Gaucha Enferm. 2013 Sep;34(3):138-46. (PMID: 24344596)
Nutrients. 2021 Nov 15;13(11):. (PMID: 34836329)
Clin Exp Nephrol. 2015 Dec;19(6):1054-61. (PMID: 25697595)
Osteoporos Int. 2009 Jun;20(6):843-51. (PMID: 19190842)
Kidney Blood Press Res. 2017;42(1):33-42. (PMID: 28297698)
Clin Interv Aging. 2018 Aug 03;13:1383-1389. (PMID: 30122910)
Biol Trace Elem Res. 2021 Mar;199(3):861-873. (PMID: 32468224)
Biol Trace Elem Res. 2020 Apr;194(2):328-335. (PMID: 31385202)
Am J Nephrol. 2012;36(3):228-37. (PMID: 22948239)
Am J Kidney Dis. 2018 Jun;71(6):884-895. (PMID: 29398179)
Horm Mol Biol Clin Investig. 2017 Mar 1;29(3):79-84. (PMID: 27416617)
Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
Malays J Med Sci. 2014 Jan;21(1):58-61. (PMID: 24639613)
Med Care. 1997 May;35(5):440-53. (PMID: 9140334)
فهرسة مساهمة: Keywords: diabetic nephropathy; magnesium; microalbuminuria; osteocalcin; oxidative stress
سلسلة جزيئية: ClinicalTrials.gov NCT03824379
تواريخ الأحداث: Date Created: 20231218 Latest Revision: 20231219
رمز التحديث: 20231219
مُعرف محوري في PubMed: PMC10722944
DOI: 10.1177/20406223231214641
PMID: 38107482
قاعدة البيانات: MEDLINE
الوصف
تدمد:2040-6223
DOI:10.1177/20406223231214641